XMD8-92
Product Specifications
UNSPSC Description
XMD8-92 is a potent ERK5 (BMK1)/BRD4 inhibitor with Kds of 80 and 190 nM, respectively. XMD8-92 inhibits DCAMKL2, PLK4 and TNK1 with Kds of 190, 600 and 890 nM, respectively. Anti-cancer activity[1][2].
Target Antigen
Epigenetic Reader Domain; ERK
Type
Reference compound
Related Pathways
Epigenetics;MAPK/ERK Pathway;Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/xmd8-92.html
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CN(C1=O)C2=CN=C(N=C2N(C3=C1C=CC=C3)C)NC4=C(C=C(C=C4)N5CCC(CC5)O)OCC
Molecular Weight
474.55
References & Citations
[1]Yang Q, et al. Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.Cancer Cell. 2010 Sep 14;18(3):258-67.|[2]Yang Q, et al. Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin Cancer Res. 2011 Jun 1;17(11):3527-32.|[3]Umapathy G, et al. The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Sci Signal. 2014 Oct 28;7(349):ra102.|[4]Lin EC, et al. ERK5 kinase activity is dispensable for cellular immune response and proliferation. Proc Natl Acad Sci U S A. 2016;113(42):11865-11870.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-14443/XMD8-92-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-14443/XMD8-92-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1234480-50-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1192180 Inquire
Recombinant Corynebacterium aurimucosum ATP synthase subunit alpha (atpA), partial
Ask
View Details 